2023 World Conference on Lung Cancer (Posters)-P2.12. Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients with and without Cardiac Comorbidities

P2.12. Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients with and without Cardiac Comorbidities - PDF(Slides)

Back to course

Pdf Summary

In a study of patients with stage-IV non-small cell lung cancer (NSCLC) who received targeted therapy, researchers found that cardiotoxicity was more prevalent in patients with comorbid heart diseases compared to those with other comorbidities. Out of 701 patients, 15 (1.8%) developed cardiotoxicities, and all of them had comorbidities. Patients with cardiac comorbidity had a significantly higher risk of therapy-related cardiotoxicity compared to those with other comorbidities. The study analyzed the cardiotoxicity rates for different targeted drugs, with the highest rates observed for amivantamab and vatalanib (100%), followed by lorlatinib and brigatinib (20-25%), and crizotinib, alectinib, and ceritinib (5-6%). The study also examined survival outcomes and found that patients with cardiotoxicity had better survival compared to those without cardiotoxicity. However, in the subgroup of patients treated with osimertinib, those with cardiac comorbidity had worse survival than those without. The study highlighted the need for further research to validate these findings, identify modifiable risk factors, and investigate underlying mechanisms. The limitations of the study include the small number of patients with cardiac comorbidity and cardiotoxicity, as well as the single-institution design. Overall, these findings provide insights into the relationship between comorbid heart diseases, cardiotoxicity, and survival outcomes in NSCLC patients receiving targeted therapy.

Asset Subtitle

Ping Yang

Meta Tag

Speaker Ping Yang

Topic Metastatic NSCLC: Targeted Therapy - Other

Keywords

stage-IV non-small cell lung cancer

NSCLC

targeted therapy

cardiotoxicity

comorbid heart diseases

comorbidities

therapy-related cardiotoxicity

targeted drugs

survival outcomes

osimertinib